VA
SANA icon

Vident Advisory’s Sana Biotechnology SANA Stock Holding History

Vident Advisory’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,645
Closed -$69.7K – 1724
2025
Q3 		$69.7K Sell
19,645
-17,220
-47% -$62.3K ﹤0.01% 1614
2025
Q2 		$101K Sell
36,865
-22,752
-38% -$46.9K ﹤0.01% 1566
2025
Q1 		$100K Buy
59,617
+16,326
+38% +$45.6K ﹤0.01% 1507
2024
Q4 		$70.6K Buy
43,291
+12,861
+42% +$38.4K ﹤0.01% 1417
2024
Q3 		$127K Buy
30,430
+1,491
+5% +$7.83K ﹤0.01% 1366
2024
Q2 		$158K Buy
28,939
+1,880
+7% +$15K ﹤0.01% 1318
2024
Q1 		$271K Buy
27,059
+1,889
+8% +$14.2K 0.01% 1088
2023
Q4 		$103K Buy
25,170
+14,924
+146% +$55K ﹤0.01% 1278
2023
Q3 		$39.7K Buy
+10,246
New +$55.1K ﹤0.01% 1239

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Vident Advisory's SANA Position: Q4 2025 in Review

Vident Advisory sold out of Sana Biotechnology (SANA) in Q4 2025, closing a stake of 19,645 shares — an estimated $69.7K sold.

Vident Advisory first reported a position in SANA in Q3 2023 and held it in 9 quarters. The position peaked at $271K in Q1 2024. 203 funds tracked by Wall St. Rank hold SANA as of Q4 2025.

  • Vident Advisory reported no remaining Sana Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Vident Advisory sold 19,645 Sana Biotechnology shares in Q4 2025, an estimated $69.7K.
  • Vident Advisory first reported a position in Sana Biotechnology in Q3 2023 and held it in 9 quarters.
  • Vident Advisory's Sana Biotechnology position peaked at $271K in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2025.

Based on Vident Advisory's 13F filing for Q4 2025, filed 18 Feb 2026.